A095700 Stock Overview
Operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Genexine, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩7,440.00 |
52 Week High | ₩12,300.00 |
52 Week Low | ₩5,840.00 |
Beta | 0.94 |
11 Month Change | 7.83% |
3 Month Change | 3.33% |
1 Year Change | -25.08% |
33 Year Change | -88.44% |
5 Year Change | -81.29% |
Change since IPO | -28.62% |
Recent News & Updates
We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt
Jul 12Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?
Mar 14Shareholder Returns
A095700 | KR Biotechs | KR Market | |
---|---|---|---|
7D | 2.6% | 1.5% | 1.9% |
1Y | -25.1% | 38.5% | 5.0% |
Return vs Industry: A095700 underperformed the KR Biotechs industry which returned 38.5% over the past year.
Return vs Market: A095700 underperformed the KR Market which returned 5% over the past year.
Price Volatility
A095700 volatility | |
---|---|
A095700 Average Weekly Movement | 6.1% |
Biotechs Industry Average Movement | 9.5% |
Market Average Movement | 6.5% |
10% most volatile stocks in KR Market | 12.1% |
10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A095700 has not had significant price volatility in the past 3 months.
Volatility Over Time: A095700's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 86 | n/a | www.genexine.com |
Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells. Its product pipeline includes GX-H9, which is in Phase II and III clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E4 that is in Phase III clinical trials for the treatment of anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; GX-I7, a product candidate in Phase I and II clinical trials to treat solid tumors, lymphopenia, and COVID-19; GX-P1, which is in Phase I clinical trials for the treatment of autoimmune diseases and transplantation; and GX-G6 that is in Phase II clinical trials for the treatment of diabetes.
Genexine, Inc. Fundamentals Summary
A095700 fundamental statistics | |
---|---|
Market cap | ₩308.39b |
Earnings (TTM) | -₩54.53b |
Revenue (TTM) | ₩5.81b |
53.1x
P/S Ratio-5.7x
P/E RatioIs A095700 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A095700 income statement (TTM) | |
---|---|
Revenue | ₩5.81b |
Cost of Revenue | ₩6.00b |
Gross Profit | -₩196.75m |
Other Expenses | ₩54.33b |
Earnings | -₩54.53b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.32k |
Gross Margin | -3.39% |
Net Profit Margin | -938.81% |
Debt/Equity Ratio | 23.8% |
How did A095700 perform over the long term?
See historical performance and comparison